Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

PHASE3CompletedINTERVENTIONAL
Enrollment

445

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Esophagitis, RefluxEsophagitis, Peptic
Interventions
DRUG

Dexlansoprazole MR

Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.

DRUG

Dexlansoprazole MR

Dexlansoprazole MR 60 mg, orally, once daily for up to six months.

DRUG

Placebo

Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.

Trial Locations (98)

Unknown

Huntsville

Tuscon

Anaheim

Azusa

Carmichael

Chula Vista

Cypress

Fresno

Garden Grove

Harrisburg

Irvine

Lancaster

Mission Hills

Oakland

Orange

Pasadena

San Diego

San Luis Obispo

Boulder

Colorado Springs

Wheat Ridge

Boynton Beach

Jupiter

Miami

New Smyma Beach

Ocala

St. Petersburg

Zephyrhills

Atlanta

Honolulu

Boise

Moline

Oak Forrest

Rockford

Clive

Lexington

Baton Rouge

Metairie

Chevy Chase

Hollywood

Lutherville

Prince Federick

Chaska

Jackson

Jefferson City

Washington

Egg Harbor

Albuquerque

Binghamton

Rochester

Greensboro

High Point

Raleigh

Bismarck

Dayton

Mogadore

Oklahoma City

Medford

Portland

Duncansville

Lansdale

Anderson

Mt. Pleasant

Bristol

Chattanooga

Germantown

Jackson

Kingsport

Nashville

Amarillo

Fort Worth

Houston

San Antonio

Ogden

Charlottesville

Chesapeake

Spokane

Tacoma

Milwaukee

Monroe

Kippa-Ring

St. John's

Newmarket

Richmond Hill

Toronto

Longueuil

Regina

Hradec Králové

Tallinn

Riga

Valmiera

Kaunas

Panevezys

Vilnius

Bratislava

Nitra

Prešov

Sučany

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY